

# SABR Symposium 2023

FFFF





# **CONVENOR WELCOME MESSAGE**

Thank you for joining us at the Peter MacCallum Cancer Centre SABR Symposium 2023. This symposium is designed for all three of the tripartite disciplines that are essential for high quality delivery of SABR; the physicist, the therapist and the oncologist. The use of SABR as a tool for treating cancer has captured the imagination of not only radiation oncologists, but other cancer clinicians and researchers.

This year we are grateful to the wonderful international faculty who have come to present their work, namely Drs Anna Bruynzeel (Netherlands), Laura Dawson (Canada), Jimm Grimm (United States), Piet Ost (Belgium) and David Palma (Canada). We're also privileged to welcome Paul Keall back to Melbourne for the always entertaining SABR Symposium Debate. After the success of our first "off-site" Symposium, we continue our tour of Parkville and are sure you will enjoy the 2023 event at the Florey Institute. We are also delighted that we can once again welcome you to the beautiful VCCC building that houses Peter Mac on Friday evening to share a drink and catch up with friends and colleagues at our Welcome Reception with a view!

We hope you enjoy the educational program and interactive discussions planned over the next two days. For those of you who attended the SIGA workshop yesterday, we hope to have your engagement and support as this organisation continues to grow.

Prof Shankar Siva, Convenor, on behalf of the Organising Committee

## **ORGANISING COMMITTEE**

MELISSA BARBER MARK BURNS SARAT CHANDER TOM DEVEREUX

LISA HALL NICK HARDCASTLE TOMAS KRON ANDREW LIM MARK SHAW KENTON THOMPSON GLENN TRAINOR KATRINA WOODFORD

# PROGRAM

#### FRIDAY 17TH NOVEMBER 2023

TIME	EVENT	SPEAKERS
815	Registration	
845	Acknowledgement of country & Welcome Address	Dr Ricky Johnston Dr Sandro Porceddu Dr Shankar Siva
	SESSION 1	Chair: Dr Shankar Siva
900	<b>Treating Oligometastatic Cancers</b> – Insights from Clinical Trials, and Implications for Practice	Dr David Palma
945	SABR for oligometastatic prostate cancer – is delaying systemic therapy meaningful or wishful thinking	Dr Piet Ost
1030	BREAK	
	SESSION 2 Sponsored by Varian	Chair: Dr Katrina Woodford
1100	Practical considerations and lessons learned over two decades of liver SABR	Dr Laura Dawson
1145	<b>Interactive session #1:</b> Complex Planning Situations - Breaking the boundaries	<b>Facilitators</b> : Dr Katrina Woodford Dr Steven David Dr Vanessa Panettieri
1245	Group Photo	Florey Foyer
1300	Lunch Break Sponsored by Varian	
	SESSION 3	Chair: Dr Nick Hardcastle
1400	<b>Overview of outcomes modelling:</b> how we arrive at dose tolerance limits in SABR	Dr Jimm Grimm
1440	<b>Expert panel discussion #1:</b> Re-irradiation – Risks and Trade-offs	<b>Facilitators:</b> Dr Mark Shaw and Dr Nick Hardcastle (with the 5 International Speakers)
1520	Break	
	SESSION 4	<b>Chair &amp; Adjudicator:</b> Dr Vanessa Panettieri
1550	SABR in primary kidney cancer	Dr Anna Bruynzeel
1630-1720	<b>Debate Sponsored by Brainlab:</b> "In five years time, SABR will be (mostly) single-day plan-and-treat"	<b>Negative:</b> Dr Paul Keall <b>Affirmative:</b> Dr Tomas Kron
1730 – 1930	Welcome Reception, Level 13 Event Space, Peter Mac, 305 Grattan St, Parkville	

## PROGRAM

#### SATURDAY 18TH NOVEMBER 2023

TIME	EVENT	SPEAKERS	
	SESSION 5	Chair: Dr Sarat Chander	
900	SABR for primary liver cancer: Ready for prime time	Dr Laura Dawson	
940	SABR with immunotherapy; synergy, abscopal effects and practical applications	Dr Piet Ost	
1020	BREAK		
	SESSION 6	Chair: Dr Tomas Kron	
1100	Adaptive SABR in the upper abdomen – Clinical Practice	Dr Anna Bruynzeel	
1145	Comparison of robotic radiosurgery motion management to the capabilities of other equipment	Dr Jimm Grimm	
1230	<b>Expert panel discussion #2</b> SABR: "Things are only impossible until they're not"	<b>Moderator:</b> Dr Shankar Siva (with the 5 International Speakers)	
1315	Lunch Break Sponsored by Brainlab		
	SESSION 7	Chair: Dr Mark Shaw	
1415	<b>Interactive session #2:</b> Smart preparation to simplify success	<b>Facilitators:</b> Dr Sarat Chander, Mark Burns & Dr Adam Yeo	
1515	SABR for Primary NSCLC – Challenges and Opportunities	Dr David Palma	
1600	Summary and closing comments	Dr Shankar Siva	
1620	Symposium Close		



### **DR. ANNA BRUYNZEEL**

Dr. Anna Bruynzeel is originally from Middelburg, the nicest town near the south-west coast of The Netherlands. She earned her medical degree (2000, cum laude) at the Erasmus University Rotterdam. From 2001-2006 she worked as a resident in Internal Medicine (Spaarne Hospital, Haarlem), followed by a residency in Medical Oncology at the VU University Medical Center Amsterdam. Anna defended her PhD thesis 'Clinical and preclinical aspects of monoHER in combination with Doxorubicine' in 2007, thereafter, completing her residency training in Radiation Oncology at the VU University Medical Center. She was appointed as a staff member in 2012. In addition to a special interest in Neuro-Oncology and intracranial radiosurgery, Anna has been a core member of the clinical team setting up the MR-guided adaptive radiotherapy program at the Amsterdam University Medical Center since 2015. Anna currently serves as the clinical lead for adaptive MR-guided radiotherapy at the Amsterdam UMC, having set up the clinical program for prostate-, renal- and pancreatic cancer. At the end of 2022, well over 1500 patients had been treated with MR-guided radiotherapy at Amsterdam UMC, including nearly 150 patients with (recurrent) renal cancer. Anna also oversees several multicentre pancreatic cancer studies and supervises PhD students.



#### LAURA DAWSON

Laura Dawson is Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is an internationally recognized leader in hepatobiliary cancer and in oligometastases. Her research has primarily focused on implementation of advanced radiation technologies (e.g. stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT)) to improve outcomes and to reduce the risk of toxicity of cancer patients. She has led phase I, II and more recently, phase III clinical trials of radiation therapy to treat patients with hepatocellular carcinoma and liver metastases. Dr. Dawson has published over 200 scientific papers and has mentored over 50 students from around the world. She has received numerous awards for her teaching, research and impact in oncology. She was the 2018 Canadian Association of Radiation Oncology (CARO) Gordon Richards lecturer, and she is the past Chair and past President of the American Society for Radiation Oncology (ASTRO).



## **DR. JIMM GRIMM**

Dr. Jimm Grimm, PhD, is a clinical physicist who analyzes radiation dose response. He has commissioned several CyberKnife systems and provided physics support for thousands of SABR cases. Dr. Grimm designed the DVH Evaluator, an FDA-cleared software tool that aids with comparing radiation therapy treatment plans to applicable dose tolerance limits, and for recording follow-up patient response and symptoms. The software has been used in the statistical tumor control probability (TCP) and normal tissue complication probability (NTCP) dose response modeling of data from more than 30,000 SBRT cases for several published clinical datasets including the full April 2016 issue of Seminars in Radiation Oncology on NTCP for SABR, as well as the May 2021 Special Issue of the Red Journal on HyTEC: High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic. Dr. Grimm is very appreciative of the more than 100 experts and authors who made these works possible.



## **PIET OST**


Piet Ost is an associate professor at Ghent University, Ghent, Belgium and radiation oncologist at the Iridium Network, Antwerp, Belgium. He is an expert in the treatment of genitourinary malignancies with a focus on prostate and bladder cancers. His research focuses on the implementation of stereotactic body radiotherapy (SBRT), oligometastases and drug-radiotherapy trials. Dr. Ost has led numerous clinical trials exploring the potential benefit of SBRT for oligometastases and radioimmunotherapy. He serves as a reviewer for several grant organizations and journals. He is a co-author of the ESMO clinical prostate cancer practice guidelines and the 2-yearly Advanced Prostate Cancer Consensus Conference, Dr. Ost is the chair of the Radiation Oncology Scientific Council of the EORTC.

Dr Ost received his M.D. degree at Ghent University in 2006, his PhD in 2011 and completed his radiation oncology training in 2012 at the same university.

1		
	<b>1</b>	
	and the second s	
	IJ	

## **DR. DAVID PALMA**

Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master's Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, and he is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.



## PROFESSIONAL DEVELOPMENT CREDIT

We have sought approval of the 2023 SABR Symposium from the three peak bodies representing SABR professionals enabling attendees to claim CPD hours, namely:



The Royal Australian and New Zealand College of Radiologists°

RANZCR The Royal Australian and New Zealand College of Radiologists

CPD hours can be claimed for attendance at the 2023 SABR Symposium. Attendees may claim 12¼ CPD hours for attending the full meeting (17th & 18th November). For anyone who attends only part of this meeting, CPD hours may be claimed pro rata equivalent to the hours attended.



ACPSEM

The Australasian College of Physical Scientists and Engineers in Medicine

The 2023 SABR Symposium has been endorsed by ACPSEM and attendees will be able to claim 2 CPD points per hour of the meeting attended, to a maximum of 10 points per day.



ASMIRT The Australian Society of Medical Imaging and Radiation Therapy

This event has been granted approval as a professional development activity by ASMIRT. The Appellation number/ unique activity code for the SABR Symposium is PMACCC-003270

## **SPONSORS**

The organising committee wishes to acknowledge the support and thank the following sponsors of the 2023 SABR Symposium

**DIAMOND:** 



### **PLATINUM:**



**GOLD**:





SILVER:

visiont nlter

# THANK YOU

# SABR Symposium 2023

